Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07696338 · ClinicalTrials.gov registry record · NA
Rethinking Early Airway Clearence Therapies
A NA study, sponsored by Nicole Hamblett.
- Not yet
- Registry status
- NA
- Development phase
- 405
- Enrollment target
NCT07696338 is a NA study that has not yet begun recruiting, run by Nicole Hamblett. The registered enrollment target is 405 participants.
The verdict
NCT07696338, a NA study, has not yet begun recruiting, sponsored by Nicole Hamblett.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 405 participants
- Enrollment target
Study Summary
The REACT trial consists of two parallel, randomized studies; the Hypertonic Saline Study and the Dornase Alfa Study. Health outcomes among people with cystic fibrosis (CF) have been steadily improving, most recently with the advent of highly effective modulator therapy (HEMT). While therapies like hypertonic saline (HS) and dornase alfa (DA) improved outcomes in the past, they are often burdensome. Now that almost 90% of the North American CF population is being treated with elexacaftor/tezacaftor/ivacaftor (ETI) or vanzacaftor/tezacaftor/deutivacaftor (VTD), this trial will evaluate whether these newer treatments make daily HS or DA unnecessary. The trial begins with a 6-week run-in period where participants continue ETI or VTD but stop using HS and DA. Eligible participants are then assigned to either the HS Study or the DA Study for one year. Within those groups, they are randomized to either daily use of HS or DA or as needed use only during respiratory illnesses. The study aims to find out if lung health is similar between children and teens taking HEMT who use HS or DA treatments daily and those who use HS or DA treatments only when they are sick.
Interventions
- OTHER As-needed hypertonic saline (HS)
- OTHER Twice daily hypertonic saline (HS)
- OTHER As-needed dornase alfa (DA)
- OTHER Daily dornase alfa (DA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 405 participants |
| Start Date | 2026-09-15 |
| Est. Completion | 2030-02-28 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07696338
The ClinicalTrials.gov registry entry for NCT07696338 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 405 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nicole Hamblett, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which As-needed hypertonic saline (HS) is the first listed.
NCT07696338 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07696338 about?
NCT07696338 is a clinical study titled "Rethinking Early Airway Clearence Therapies". The REACT trial consists of two parallel, randomized studies; the Hypertonic Saline Study and the Dornase Alfa Study. Health outcomes among people with cystic fibrosis (CF) have been steadily improving, most recently with the advent of highly effective modulator therapy (HEMT). While therapies like...
What is the current status of trial NCT07696338?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 405 participants. The study started on 2026-09-15. Estimated completion is 2030-02-28.
What interventions are being tested in trial NCT07696338?
The interventions under investigation include: As-needed hypertonic saline (HS) (OTHER), Twice daily hypertonic saline (HS) (OTHER), As-needed dornase alfa (DA) (OTHER), Daily dornase alfa (DA) (OTHER).
Who is sponsoring clinical trial NCT07696338?
This trial is sponsored by Nicole Hamblett, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.